Proteoral is the first excipient transports biological active pharmaceutical ingredients through the intestine by safely opening intercellular junctions of the intestinal epithelium
Learn More 
Most therapeutic biological products are injectable. However, oral medications are the patients first choice of drug intake. Proteoral is the solution as it transports biological active pharmaceutical ingredients through the intestine, using pills instead of shots.
Proteoral is friendly to humans and the planet.
A homogeneous solution of your biological pharmaceutical active ingredient and the Proteoral excipient is obtained.
A homogeneous powder suitable for the encapsulation of your biological pharmaceutical active ingredient and the Proteoral excipient is obtained.
Your active ingredients and Proteoral are encapsulated in capsules that protect from stomach action and are quick - release at the small intestine.The active ingredient released is rapidly absorbed in the intestine with Proteoral into the bloodstream reaching its site of action.
Be a game changer in your market with your oral biological product.
Our versatile formulation platform protects your active ingredients in capsules and releases them in the small intestine. The active ingredient is absorbed with Proteoral into the bloodstream.
.Initial non-clinical trial had demonstrated that Proteoral is safe and effective.
Proteoral is a recombinant protein produced by biotechnology with low manufacturing costs. Its mechanism of action is completely innocuous, it opens the intercellular junctions of the intestine and transports your product to the bloodstream, reaches the target site and fulfills its therapeutic action. Be a pioneer in your segment with your oral biological medicinal product!
High Quality Oral Biologics medicinal products by Design.
Faster pharmacokinetic and pharmacodynamic studies.
Manufacture in accordance to GLP/GMP preclinical and clinical phases standards
Technical transfer to the manufacturing site Supported
Production and on-site troubleshooting supported.
Friendly to humans and the planet.
We benefit the lives of humans by transforming the industry through oral biological medicines.
To be a prefered partner in the pharmaceutical industry and medicine by incorporating new products and scientific discoveries into the market.
Through our ethics, commitment to medicine, and global vision, we contribute to Wellness and Health with a global impact.
We connect, inspire, empower technologists and scientists become the innovations found in the world’s most impactful companies.
Top Pre-Accelerator & Incubator In Silicon Valley.
We partner with those who rebuild society through empathy and technology.
Fondo Fiduciario Para el Desarrollo de Capital Emprendedor (FONDCE).
IB50K
Universidad Austral
Centro de Medicina Comparada
Universidad del Litoral
Universidad de Buenos Aires
What is the biological activity of Proteoral?
Proteoral is a pore-forming protein opening the intercellular junctions of the small intestine.
What is the type of transportation?
Biologics active ingredients are transported by paracellular transepithelial passage through the small intestine and absorbed into the bloodstream.
What are the molecules it transports?
Proteoral can transport macromolecules: Hormones, monoclonal antibodies, peptides, polysaccharides and other macromolecules.
Is there any size limit for loading?
Proteoral transports macromolecules from peptides from 5 Kda to more than 147 Kda.
When does Proteoral have its peak activity?
The activity of Proteoral begins 20 minutes after the release of the product in the intestine, and the greatest absorption is achieved 2 hours after oral -administration.
What is the region of maximum absorption in the intestine?
The region of maximum absorption is the duodenum and jejunum-ileum in the small intestine.
Panarum S.A.S. has been selected to participate in @villagecapital ‘s Innovations in Health LatAm acceleration...
2025-02-17
The Proteoral Project received a distinction for being one of the 10 finalists of the IX Israel Innovation...
2024-11-21
Panarum S.A.S. awarded, the second best STARTUP at the Santander X Argentina Award STARTUPS
2024-11-01
Proteoral is selected for the final stage of the IX edition Israel Innovation Award
2024-10-18
Milena Batalla, Ph.D. Founder and CEO of Panarum S.A.S. is a finalist in the Santander X Argentina Award...
2024-10-01
The founder & C.E.O. of the startup Panarum completes preclinical studies of the Proteoral protein...
2024-04-04
Milena Batalla, Ph.D. author in Annals of the Argentine Chemical Association, Vol.110 N°2.
2024-02-24
PANARUM has been received FONARSEC EMPRETECNO 2023 Grant 22-11-2023
2024-01-30
Proteoral exported to a multinational Company in Darmstadt, Germany
2023-08-11
Milena Batalla, Ph.D. author on . All-natural 5-MeO-DMT sigma receptor 1 agonist and its therapeutic...
2023-07-31
PANARUM joined to CONICET to celebrate the 65 Anniversary 1958 – 2023 of the Consejo Nacional de Investigaciones...
2023-04-10
STANFORD Latino Entrepreneurship Initiative Education SCALING Program GRADUATION CEREMONY.
2022-12-03
Milena Batalla, Ph. D. joins to the STANFORD Latino Entrepreneurship Initiative Education SCALING Program....
2022-10-01
Meeting of Women Entrepreneurs at the Secretariat of Industry and Productive Development of Argentina
2022-09-21
Draper Startup House Ventures is pleased to back Panarum Corp, which is revolutionizing oral proteins.
2022-06-01
Proteoral introduced at The American Association of Pharmaceutical Scientists Virtual Workshop
2022-04-11
Panarum at The Silicon Review magazine, 1st September 2021
2021-09-01
Milena Batalla, PANARUM CEO invited among Latin American women in Science in the 25th issue of Quimiofilia...
2021-08-03
Panarum the winner in Draper University First Position on Demo Day
2021-07-28
Entrepreneurship to innovate
2021-07-13
Milena Batalla was selected to participate in the Draper University Summer 2021 Pre-Accelerator Program.
2021-07-05
PANARUM introduced Proteoral in the Casa Rosada, Argentina
2021-06-11
Draper Cygnus invested US$640k in Panarum, an Argentine biotech creates Proteoral to replace the use...
2020-12-21
Panarum in the Magazine of Drug Delivery New Oral Delivery Systems # 109
2020-07-31
